Search Results within category "Lung Disease & Asthma"
Search all categoriesSuggestions within category "Lung Disease & Asthma"
10
Study Matches
A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with idiopathic pulmonary fibrosis
This study will evaluate the effectiveness and safety of study drug PRM-151 compared with placebo in patients with idiopathic pulmonary fibrosis
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
NCT04552899
Lung Disease & Asthma
Site For VIOLET
Site For VIOLET
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
All
18 year(s) or older
N/A
Infectious Diseases & Immune System, Lung Disease & Asthma
Effects of antibiotic use on fecal microbiome and resistome
This study will investigate the changes in the human fecal microbiomes and resistomes in response to antibiotic treatment.
Jasna Kovac at jzk303@psu.edu or 814-699-1680
All
18 year(s) or older
N/A
Infectious Diseases & Immune System, Lung Disease & Asthma
Evaluating the Cough Reflex in Fibrotic and Healthy Lungs
Determining cough threshold in patients with fibrotic lung disease and in healthy controls by stimulating cough.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
N/A
Lung Disease & Asthma
PSCI 21-064: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
A study designed to evaluate the efficacy and safety of BGB-A1217 + tislelizumab compared with that of pembrolizumab in patients with
PD-L1-selected NSCLC who have locally advanced or recurrent disease that is unresectable or not amenable to radiotherapy, with or without chemoradiotherapy, or previously untreated metastatic disease, and whose tumors do not harbor EGFR-sensitizing mutations or ALK translocations. The efficacy and safety of tislelizumab alone will be explored in a small cohort of the same patient population.
Kathleen Rizzo at krizzo@pennstatehealth.psu.edu or 717-531-0003, ext=289630
All
18 year(s) or older
NCT04746924
Lung Disease & Asthma
A 52-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
Placebo-controlled efficacy and safety study of GSK3511294 in participants with severe asthma with an eosinophilic phenotype
Hunter Smith at hsmith16@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
NCT04718103
Lung Disease & Asthma
Recruitment for Nicotine and Tobacco Related Research at Penn State Hershey
The purpose of this project is to screen potential participants for multiple research studies being conducted by tobacco researchers at Penn State Hershey.
Since there are multiple IRB approved studies enrolling at Penn State Hershey with similar but not identical inclusion/exclusion criteria, it is more efficient for the researchers and participants to have one phone number to call initially for basic screening. After completing this, the participant can be redirected for more specific screening if they are found to be potentially eligible for one of the studies.
Candace Bordner at cbordner@phs.psu.edu or 844-207-4594
All
18 year(s) or older
N/A
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Lung Disease & Asthma
A Survey to Estimate the Socio-Economic Impact of the Novel Corona Virus (COVID-19) Pandemic
We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.
Pritish Mondal at pmondal@pennstatehealth.psu.edu or 717-897-0652
All
18 year(s) or older
N/A
Infectious Diseases & Immune System, Prevention, Lung Disease & Asthma
A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF)
Assessment of the safety and tolerability of PLN-74809 following daily administration for up to 28 days in patients with idiopathic pulmonary fibrosis
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
NCT04396756
Lung Disease & Asthma
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.
Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.
Kristina Richwine at krichwine@pennstatehealth.psu.edu or 717-531-4506
All
18 year(s) or older
NCT04718389
Lung Disease & Asthma